1-855-378-42281-855-378-4228
One of the out-patient rehabilitation options for individuals in Ossining struggling with opioid dependence and addiction is called opioid maintenance therapy. Licensed facilities and doctors are certified to give specific medications to opioid addicted people, many of which are opioid-based themselves and are addictive. With low enough doses however, the individual doesn't feel high but also does not have intense cravings and is not in opioid withdrawal. Methadone is the first drug tried for this sole purpose, but there are alternative choices to pick from.
Methadone is an opioid and is meant to be taken at an out-patient medical center licensed to dispense the med, which is taken on a daily basis as a pill or liquid. The price of the med is around one hundred and fifty dolloars a month. Buprenorphine is also an opioid-based med, and is a pill often taken one day on, one day off. But unlike Methadone that is only be given in highly well-regulated medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The price monthly of buprenorphine is approximately just under $300 /month for the generic version of the drug. There is also a version of buprenorphine that contains the ingredient naloxone, which is a med that blocks the effects of opioids. Someone taking this formulation, AKA Suboxone, would find it harder to get high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and is priced around $450 monthly. Naltrexone is an additional medication taken in opioid maintenance therapy, but unlike the other medications aforementioned it's an opioid blocker and isn't an opiate. A person has the choice to take this drug as a monthly shot, and that is called Vivitrol. As an opioid blocker, the drug prevents a person from getting high from opioids, and in turn lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 a month.
For All Alcohol and Drug Rehab Facilities In Ossining, Click Here.
